Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: Cardiac iron and function comparison determined by quantitative magnetic resonance imaging

Haematologica

Volumn 96, Issue 1, 2011, Pages 41-47

  Pepe, Alessia ^a   Meloni, Antonella ^a   Capra, Marcello ^b   Cianciulli, Paolo ^c   Prossomariti, Luciano ^d   Malaventura, Cristina ^e   Putti, Maria Caterina ^f   Lippi, Alma ^g   Romeo, Maria Antonietta ^h   Bisconte, Maria Grazia ⁱ   Filosa, Aldo ^d   Caruso, Vincenzo ^j   Quarta, Antonella ^k   Pitrolo, Lorella ^l   Missere, Massimiliano ^m   Midiri, Massimo ⁿ   Rossi, Giuseppe ^a   Positano, Vincenzo ^a   Lombardi, Massimo ^a   Maggio, Aurelio ^o  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b G Di Cristina Children's Hospital   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ Osp Civ Annunziata   (Italy)

^j GARIBALDI HOSPITAL   (Italy)

^k 'A Perrino' Hospital   (Italy)

^l Villa Sofia CTO Hospital   (Italy)

^m CATHOLIC UNIVERSITY   (Italy)

ⁿ UNIVERSITY OF PALERMO   (Italy)

^o VILLA SOFIA CERVELLO HOSPITAL   (Italy)

more..

Author keywords

Cardiac magnetic resonance imaging; Iron chelation therapy; Thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; PYRIDONES; RETROSPECTIVE STUDIES; SIDEROPHORES; TRIAZOLES; VENTRICULAR FUNCTION; YOUNG ADULT;

EID: 78650982192     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019042     Document Type: Article

References (31)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-93.
2. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42(3):247-51.
3. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in ß-thalassaemia. Lancet. 2002;360(9332): 516-20.
4. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, et al. Evaluation of the efficacy of oral deferiprone in ß-thalassemia major by multislice multiecho T2*. Eur J Haematol. 2006;76(3):183-92.
5. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in ß-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-44.
6. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-7.
7. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88(5):489-96.
8. Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V, et al. Risk factors for death in patients with ß-thalassemia major: results of a case-control study. Haematologica. 2006;91(10):1420-1.
9. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006; 91(9):1187-92.
10. Pennell D, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of Deferasirox in reducing and preventing cardiac iron overload in ß-thalassemia. Blood. 2010;115(12):2364-71.
11. Wood JC, Kang B, Thompson AA, Giardina P, Harmatz P, Glynos T, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-43.
12. Pathare A, Taher A, Daar S. Deferasirox (Exjade(R)) significantly improves cardiac T2* in heavily iron-overloaded patients with ß-thalassemia major. Ann Hematol. 2010;89(4):405-9.
13. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson. 2009;11 (1):20.
14. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22 (23):2171-9.
15. Pepe A, Positano V, Santarelli F, Sorrentino F, Cracolici E, De Marchi D, et al. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging. 2006;23(5):662-8.
16. Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K, et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging. 2005;21(5):531-8.
17. Positano V, Salani B, Pepe A, Santarelli MF, De Marchi D, Ramazzotti A, et al. Improved T2* assessment in liver iron overload by magnetic resonance imaging. Magn Reson Imaging. 2009;27(2):188-97.
18. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973-8.
19. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10(1):42.
20. Sironi M, Lombardi M, Pepe A, De Marchi D. Study of heart function In: eds. S-VI, editor. MRI of Heart and Vessels Lombardi M, Bartolozzi C; 2005.
21. Ramazzotti A, Pepe A, Positano V, Rossi G, De Marchi D, Brizi MG, et al. Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron. J Magn Reson Imaging. 2009;30(1):62-8.
22. Meloni A, Ramazzotti A, Positano V, Salvatori C, Mangione M, Marcheschi P, et al. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia. Int J Med Inform. 2009;78:503-12.
23. Positano V, Pepe A, Santarelli MF, Scattini B, De Marchi D, Ramazzotti A, et al. Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. NMR Biomed. 2007;20:578-90.
24. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539-42.
25. Aessopos A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, Giakoumis A, et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusiondependent thalassemia. Haematologica. 2007;92(1):131-2.
26. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusiondependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-5.
27. Positano V, Pepe A, Santarelli MF, Ramazzotti A, Meloni A, De Marchi D, et al. Multislice multiecho T2* cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients. NMR Biomed. 2009;22(7):707-15.
28. Westwood MA, Anderson LJ, Maceira AM, Shah FT, Prescott E, Porter JB, et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging. 2007;25(6):1147-51.
29. Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev. 2005(4):CD004450.
30. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006; 8(3):543-7.
31. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with ß-thalassemia. Blood. 2006;107(9):3455-62.